Suggested remit - To appraise the clinical and cost effectiveness of gilteritinib within its marketing authorisation for treating relapsed or refractory positive acute leukaemia
 
Status In progress
Process STA 2018
ID number 1484

Provisional Schedule

Expected publication 26 February 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors Astella Pharma Ltd (gilteritinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Bloodwise
  Leukaemia Care
Professional groups Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Bristol-Myers Squibb Pharmaceuticals Ltd (hydroxycarbamide) – confidentiality agreement signed
  Pfizer (cytarabine, idarubicin) – confidentiality agreement signed
  Accord Healthcare Ltd (cytarabine, fludarabine, idarubicin,) – confidentiality agreement not signed
  Actavis (fludarabine) – confidentiality agreement not signed
  Amgen (filgrastim) – confidentiality agreement not signed
  Celgene (azacitidine)
  Hospira UK (cytarabine, fludarabine, filgrastim) – confidentiality agreement not signed
  Medac UK (hydroxycarbamide) – confidentiality agreement not signed
  Napp Pharmaceuticals (cytarabine) – confidentiality agreement not signed
  Sandoz (fludarabine, filgrastim) – confidentiality agreement not signed
  Teva (fludarabine) – confidentiality agreement not signed
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
05 April 2019 Invitation to participate
05 April 2019 In progress, Committee C appraisal
15 February 2019 - 15 March 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance